Correlation of modified gleason grading of prostate carcinoma with age, serum prostate specific antigen and tumor extent in needle biopsy specimens

Analytical and Quantitative Cytology and Histology

Volumn 30, Issue 3, 2008, Pages 133-138

  Helpap, Burkhard ^a,c   Egevad, Lars ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c NONE   (Germany)

Author keywords

Adenocarcinoma; Gleason grade; Prostate; Prostate specific antigen; Tumor volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MODIFIED GLEASON GRADING; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 44949264117     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL: The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242
2. Helpap B, Egevad L: The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch 2006;449:622-627
3. Helpap B, Egevad L: The value of the modified Gleason grading system of prostate adenocarcinoma in routine urological diagnostics [German]. Urologe A 2007;46:59-62
4. Melia J, Moseley R, Ball RY, Griffiths DF, Grigor K, Harnden P, Jarmulowicz M, McWilliam LJ, Montironi R, Waller M, Moss S, Parkinson MC: A UK-based investigation of inter-and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 2006;48:644-654
5. Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L: Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens. Virchows Arch 2004;445:17-21
6. Helpap B, Egevad L: Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostectomy. Anal Quant Cytol Histol 2008;30:1-7
7. Berney DM, Fisher G, Kattan MW, Oliver T, Moller H, Fearn P, Eastham JA, Scardino P, Cuzick J, Reuter V, Foster CS: Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 2007;100:1240-1244
8. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-419
9. Egevad L, Allsbrook WC Jr, Epstein JI: Current practice of Gleason grading among genitourinary pathologists. Hum Pathol 2005;36:5-9
10. Gleason DF: Classification of prostatic carcinomas. Cancer Chemotherapy Rep 1966;50:125-128
11. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In Urologic Pathology: The Prostate. Edited by M Tannenbaum. Philadelphia, Lea and Feibiger, 1977, pp 171-198
12. Gleason DF: Histologic grading of prostate cancer: A perspective. Hum Pathol 1992;23:273-279
13. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R: Current practice of Gleason grading of prostate carcinoma. Virchows Arch 2006;448:111-118
14. Egevad L, Norlen BJ, Norberg M: The value of multiple core biopsies for predicting the Gleason score of prostate cancer. BJU Int 2001;88:716-721
15. Epstein JI: Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: A diagnosis that should not be made. Am J Surg Pathol 2000;24:477-478
16. Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R: Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol (Suppl) 2005; 216:20-33
17. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW: Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:995-1000
18. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P: Prognostic value of the Gleason score in prostate cancer. BJU Int 2002;89:538-542
19. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC: Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003;62:866-871
20. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 1997;277:1445-1451
21. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004;172:910-914
22. Draisma G, Posrma R, Schroder FH, van der Kwast TH, de Koning HJ: Gleason score, age and screening: Modeling dedifferentiation in prostate cancer. Int J Cancer 2006;119:2366-2371
23. Horninger W, Rogatsch H, Reissigl A, Volgger H, Klocker H, Hobisch A, Bartsch G: Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate 1999;40:56-61
24. Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ: Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol 1999;161:1525-1529
25. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW: Prediction of pathological stage in patients with clinical stage T1c prostate cancer: The new challenge. J Urol 2002;168:100-104
26. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP: Gleason score 7 prostate cancer: A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000;56:730-734
27. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H: Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: Differences in outcome between primary Gleason grades 3 and 4. J Urol 2001;166:1692-1697
28. Chan TY, Partin AW, Walsh PC, Epstein JI: Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000;56:823-827
29. Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS: Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000;89:135-141
30. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB: Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160:2407-2411
31. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA: Relating biopsy and clinical variables to radical prostatectomy findings: Can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004;64:544-550
32. Augustin H, Hammerer PG, Graefen M, Erbersdobler A, Blonski J, Palisaar J, Daghofer F, Huland H: Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction. Eur Urol 2003;43:455-460
33. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374
34. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT: Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies [comments]. J Urol 1996;156:1059-1063
35. Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H: Prostate specific antigen detected prostate cancer (clinical stage T1c): An interim analysis. J Urol 1996;155:821-826
36. Helpap B, Sinicina I: Diagnostic measures for therapeutic steps of prostate adenocarcinoma. Urologe (B) 2002;42:121-127
37. Epidemiologisches Krebsregister Saarland: Available at: http://www.krebsregister.saarland.de/datenbank/datenbank.html